UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report

(Date of earliest event reported)

June 28, 2016

 

MARINUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36576

 

20-0198082

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

170 N. Radnor Chester Rd, Suite 250
Radnor, PA

 

19087

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (484) 801-4670

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01.                                        Other Events.

 

On June 28, 2016, Marinus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing top-line results from a Phase 2 exploratory clinical trial with ganaxolone in Fragile X Syndrome. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.  On June 28, 2016, the Company conducted an investor conference call and webcast to discuss the results of this trial.  A copy of the slides presented during that call is filed as Exhibit 99.2 to this Current Report on Form 8-K

 

Item 9.01.                                        Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Press Release, dated June 28, 2016, of Marinus Pharmaceuticals, Inc.

 

 

 

99.2

 

Slide Presentation at Investor Conference Call and Webcast on June 28, 2016 at 9:00 a.m. ET.

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MARINUS PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ Edward Smith

 

 

Edward Smith,

 

 

Vice President, Chief Financial Officer,

 

 

Secretary and Treasurer

 

Date:  June 28, 2016

 

3